Found: 25
Select item for more details and to access through your institution.
In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4136, doi. 10.3390/cancers15164136
- By:
- Publication type:
- Article
Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
- Published in:
- Immunologic Research, 2016, v. 64, n. 3, p. 687, doi. 10.1007/s12026-015-8778-2
- By:
- Publication type:
- Article
The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
- Published in:
- Journal of Cellular Biochemistry, 2020, v. 121, n. 1, p. 407, doi. 10.1002/jcb.29195
- By:
- Publication type:
- Article
OAB-017: Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S11, doi. 10.1016/S2152-2650(21)02091-7
- By:
- Publication type:
- Article
Functional characterization of the RAL-dependent survival pathway in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e138, doi. 10.1016/j.clml.2019.09.230
- By:
- Publication type:
- Article
CD200 expressing multiple myeloma cells show increased resistance against T cell-mediated cytotoxicity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e138, doi. 10.1016/j.clml.2019.09.229
- By:
- Publication type:
- Article
A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e53, doi. 10.1016/j.clml.2019.09.081
- By:
- Publication type:
- Article
A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e61, doi. 10.1016/j.clml.2017.03.112
- By:
- Publication type:
- Article
RalA and RalB are Potential Therapeutic Targets in Multiple Myeloma Which Mediate Cell Survival Independently of Oncogenic RAS.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e110, doi. 10.1016/j.clml.2017.03.200
- By:
- Publication type:
- Article
Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Neue Formen der Immuntherapie für die Uroonkologie: HLA-unabhängige Therapieansätze mit bispezifischen Antikörpern und CAR-T-Zellen.
- Published in:
- Die Urologie, 2023, v. 62, n. 7, p. 685, doi. 10.1007/s00120-023-02117-1
- By:
- Publication type:
- Article
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 36, doi. 10.1111/bjh.14807
- By:
- Publication type:
- Article
From CLL to Multiple Myeloma - Spleen Tyrosine Kinase ( SYK) influences multiple myeloma cell survival and migration.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 6, p. 985, doi. 10.1111/bjh.13825
- By:
- Publication type:
- Article
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3 CA isoform.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 4, p. 529, doi. 10.1111/bjh.12920
- By:
- Publication type:
- Article
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 4, p. 465, doi. 10.1111/bjh.12164
- By:
- Publication type:
- Article
Combined targeting of MEK/ MAPK and PI3 K/ Akt signalling in multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 159, n. 4, p. 430, doi. 10.1111/bjh.12039
- By:
- Publication type:
- Article
Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells.
- Published in:
- Cancer Genomics & Proteomics (1109-6535), 2022, v. 19, n. 5, p. 540, doi. 10.21873/cgp.20339
- By:
- Publication type:
- Article
Efficient Transient Transfection of Human Multiple Myeloma Cells by Electroporation – An Appraisal.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0097443
- By:
- Publication type:
- Article
The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0063414
- By:
- Publication type:
- Article
Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-75499-3
- By:
- Publication type:
- Article
The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
- Published in:
- International Journal of Cancer, 2001, v. 93, n. 5, p. 674, doi. 10.1002/ijc.1388
- By:
- Publication type:
- Article
Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 8, p. 1181, doi. 10.3390/ph16081181
- By:
- Publication type:
- Article
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 11, p. 1126, doi. 10.3390/ph14111126
- By:
- Publication type:
- Article
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
- Published in:
- British Journal of Haematology, 2010, v. 149, n. 4, p. 529, doi. 10.1111/j.1365-2141.2010.08126.x
- By:
- Publication type:
- Article
Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
- Published in:
- British Journal of Haematology, 2009, v. 147, n. 3, p. 319, doi. 10.1111/j.1365-2141.2009.07852.x
- By:
- Publication type:
- Article